A polished paragraph is easy to generate. Establishing that every number in it comes from the right study is much harder.
That is the central challenge for AI-assisted regulatory writing. An Investigational New Drug application, or IND, brings together evidence supporting a proposed clinical investigation in the United States. The documents must tell a consistent story about the product, the available studies, and the planned research.
AI can help assemble and check that story. Its most useful output is a draft whose statements can be verified, whose gaps remain visible, and whose revisions can be reviewed.
The IND Challenge
The FDA describes three broad information areas : pharmacology and toxicology, manufacturing, and clinical protocols with investigator information. Together, they support assessment of whether the proposed investigation can proceed with appropriate protections for participants. An IND is distinct from approval to market a drug.
These areas depend on one another. If the clinical formulation differs from the material used in a supporting study, reviewers need to understand the difference. If a study report changes, several summaries may need revision.
A writing tool that treats each section as an isolated task can make those connections harder to maintain.
What was studied, what was observed, and what it means for the proposed investigation.
Composition, preparation, stability, and controls for consistent investigational material.
The proposed clinical study, investigator information, and participant protections.
Document completeness and scientific adequacy are separate review questions.
The Common Technical Document, or CTD, supplies an organizational framework for regulatory information. ICH’s CTD overview distinguishes regional administrative material, summaries, quality information, nonclinical reports, and clinical reports. It describes where information belongs, rather than establishing that any particular package contains enough evidence. The applicable content and submission format still depend on the product and development stage.
AI-Generated Regulatory Documentation
Start with an evidence inventory. For each source, record the study identifier, document version, status, responsible team, and location. A preliminary analysis and a finalized study report should not silently become interchangeable inputs.
Then define which sources a drafting task may use. A request to summarize a specific study should retrieve that study and preserve references to the relevant tables or sections. It should not fill a missing detail from a paper about a different compound.
Structured extraction can help with repeated fields such as product names, study durations, units, and report dates. Drafting can turn checked fields into readable prose. Consistency checks can compare the same field across documents. These are useful, separable tasks with different failure modes.
Source retrieval, extraction, drafting, and scientific acceptance each need a check. Passing one does not establish the others.
The Speed Advantage
The most credible time savings come from avoiding repeated assembly: searching for a report, copying a table, rebuilding a reference, or checking whether a draft uses the current product name.
Suppose a study report is revised. A source-linked workflow can identify the passages that depend on it and present them for review. That is more useful than regenerating every section and asking a specialist to rediscover what changed.
Measure time through acceptance of the reviewed draft, including corrections. A system that produces text quickly but introduces hard-to-find errors may increase the total workload.
Quality and Auditability
A draft statement needs more than a citation-shaped marker. The referenced source must exist, match the correct product and study, and support the actual wording. “No finding was observed in this study” is a narrower statement than “the product has no such risk.”
Numerical checks should preserve units and denominators. A concentration, a dose, and an exposure measurement are different quantities. A writer should not convert or compare them without the relevant context and a reviewed method.
The workflow should also retain disagreement. If two documents conflict, show the conflict and assign it for resolution. Choosing whichever value appears most often can turn a duplicated mistake into an apparently authoritative answer.
Where Expert Review Belongs
Scientific and regulatory specialists assess the adequacy of the evidence, its relevance to the proposed investigation, and the conclusions drawn from it. Software can help them locate material and identify possible inconsistencies. It cannot make an absent study appear or settle an unresolved safety interpretation by writing confidently.
FDA’s pharmacology and toxicology information page explains that the scope of supporting studies depends on the nature and duration of the proposed investigation. That connection is why a generic checklist is insufficient for deciding readiness.
Implications for the Industry
At AgentCures, keeping analyses and drafts connected to a version-controlled research record is part of our approach. The aim is to support review throughout a program, rather than reconstruct its history at the end.
A practical first deployment would be narrow: one study summary, a defined source set, and a reviewer who can inspect every extracted value. Expand only after the team understands the errors and can show that corrections are captured reliably.
The valuable deliverable is an evidence package that people can check and maintain. Better prose helps, but traceability is what makes the prose useful.